The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis

Published: April 2020


The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research 

Roots Analysis has announced the addition of RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings. 

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. 

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link 

Key Market Insights 

Over 170 RNAi therapeutics are currently under development 
Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell. 

More than 70% of ongoing clinical trials are being conducted in North America and Europe
In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs.

Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014
Majority of these were patent applications (59%), followed by granted patents (40%). It is worth highlighting that both industry and non-industry players are actively involved in this domain. However, majority of the patents related to RNAi therapeutics were filed / granted by industry players (60%). 

USD 5.4+ billion invested by both private and public investors, since 2014
Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019. Further, there have been five instances of debt financing, accounting for more than USD 844 million in financing of RNAi therapeutics related initiatives. 

Around 65 partnerships were inked since 2014
Maximum number of deals were reported in 2018. Around 30% of the deals were related to the R&D agreements; this was followed by technology licensing agreements (27%).

RNAi therapeutics market is anticipated to increase at a CAGR of over 45% between 2019-2030
This growth is anticipated to be primarily driven by the target specificity of the drug candidates. North America (primarily the US) are expected to capture the majority share by 2030. 

To request a sample copy / brochure of this report, please visit this link    

Key Questions Answered
  • Who are the leading industry players in this market?
  • What are the clinical conditions for which RNAi therapeutics are being developed?
  • Who are the key investors in the RNAi therapeutics market?
  • What kind of commercialization strategies are being adopted by RNAi therapeutics developers?
  • What are the different promotional and reimbursement strategies used for RNAi therapeutics?
  • What are the prevalent R&D trends related to RNAi therapeutics?
  • What are the various delivery / technology platforms that are being used for the development of RNAi therapeutics?
  • What kind of partnership models are used by stakeholders in this industry? 
  • Who are the key service providers in this field of therapeutics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The USD 10 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

  • Key therapeutic areas
    • Oncological disorders
    • Infectious diseases
    • Genetic disorders
    • Ophthalmic disorders
    • Hepatic disorders
    • Respiratory disorders
  • Type of RNAi molecule
    • siRNA
    • miRNA
    • shRNA
    • sshRNA
    • DNA
  • Route of administration
    • Subcutaneous
    • Intravenous
    • Intradermal
    • Intratumoral
    • Intravitreal
    • Oral
    • Intramuscular
  • Key geographical regions 
    • North America
    • Europe
    • Rest of the World
    • Leading Players

The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry. The report includes detailed transcripts of discussions held with the following expert(s):

  • Amotz Shemi (Chief Executive Officer, Silenseed)

The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic area, indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available). 

  • Quark Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Souzhou Ribo Life Sciences
  • Olix Pharmaceuticals 
  • Sirnaomics
  • Ariz Precision Medicine
  • Arrowhead Pharmaceuticals
  • Gradalis
  • Benitec Biopharma

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

or email sales@rootsanalysis.com 

You may also be interested in the following titles: 

  1. Gene Therapy Market (3rd Edition), 2019-2030
  2. Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030
  3. Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry

-->